<DOC>
	<DOCNO>NCT00028665</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . It yet know combine rituximab cyclophosphamide effective cyclophosphamide alone stimulate peripheral stem cell transplantation . PURPOSE : This randomized phase II trial study well give cyclophosphamide without rituximab follow chemotherapy peripheral stem cell transplantation work treat patient recurrent non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Cyclophosphamide W/or W/Out Rituximab Peripheral Stem Cell Transplantation Patients With Recurrent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect mobilization therapy without rituximab hematopoietic stem cell , B T lymphocytes , natural killer cell patient advanced recurrent B-cell non-Hodgkin 's lymphoma . - Compare effect B-lymphocyte purge use concurrent rituximab mobilization therapy v CD34+ cell enrichment device hematopoietic stem cell , B T lymphocytes , natural killer cell peripheral blood stem cell ( PBSC ) infusates . - Compare effect purge regimen tumor cell content PBSC infusates . - Compare effect regimens myeloid lymphoid engraftment high-dose chemotherapy autologous PBSC infusion patient . - Compare post-transplantation infection complication patient treat regimen . - Compare response relapse-free survival patient treat regimen . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive mobilization therapy comprise rituximab IV 2-5 hour day 1 , 8 , 15 cyclophosphamide IV 3-6 hour day 16 . Beginning 36-48 hour completion cyclophosphamide , patient receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily blood count recover . Patients undergo peripheral blood stem cell ( PBSC ) collection . After completion PBSC collection , patient receive high-dose chemotherapy comprise carmustine IV day -7 -3 etoposide IV cisplatin IV 3 day day -7 -3 . Patients may undergo involved-field radiotherapy active previously bulky ( 5 cm ) tumor daily 7-10 day . Patients receive unmanipulated PBSCs day 0 . Patients receive G-CSF SC daily begin 4 hour completion PBSC infusion continue neutrophil engraftment . - Arm II : Patients receive mobilization therapy comprise cyclophosphamide G-CSF high-dose chemotherapy comprise carmustine , etoposide , cisplatin arm I . Patients may also undergo involved-field radiotherapy arm I . Patients receive CD34 cell-enriched PBSC day 0 follow G-CSF arm I . Patients follow every 3 month . PROJECTED ACCRUAL : A total 71 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Bcell nonHodgkin 's lymphoma ( NHL ) Indolent aggressive histology No small lymphocytic lymphoma , Burkitt 's lymphoma , small lymphocytic nonBurkitt 's lymphoma CD20positive and/or CD19positive immunohistochemistry flow cytometry Second great remission allow Partial remission , relapse , refractory disease must measurable tumor Eligible highdose therapy follow autologous peripheral blood stem cell transplantation No CNS involvement lymphoma PATIENT CHARACTERISTICS : Age : 12 65 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,200/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine clearance least 60 mL/min No renal dysfunction Cardiovascular : LVEF least 40 % No cardiac dysfunction No myocardial infarction within past 3 month Pulmonary : FEV_1 great 60 % DLCO least 60 % predict No pulmonary dysfunction No asthma Other : HIV negative No significant organ dysfunction No severe comorbid condition No uncontrolled diabetes No severe active infection Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Chemotherapy No prior immunotherapy Chemotherapy : No prior highdose chemotherapy without peripheral blood stem cell transplantation No 3 prior chemotherapy regimens NHL At least 4 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
</DOC>